Program Book - Confex

More documents

Recommendations

Info

Invited Speaker /Moderator Index 330 L Lacaille, Diane V., MD, MHSc Keep People with Arthritis Working: An Interactive Case-based Discussion . . . . . .106 Disclosure: Nothing to Disclose Lahita, Robert G., MD, PhD Systemic Lupus Erythematosus: Novel Treatments. . . . . . . . . . . . . . . . . . . 80 Disclosure: Nothing to Disclose Laing, Timothy, MD Legislative Update from Capitol Hill . . . . . 51 Disclosure: Nothing to Disclose Lambris, John D., PhD Complimentary Roles for Complement in the Rheumatic Diseases . . . . . . . . . . . . . . 85 Disclosure: producing, 7 Lane, Nancy E., MD ACR REF Oscar S. Gluck, MD, Memorial Lectureship: Everything a Rheumatologist Should Know About Glucocorticoid-Induced Bone Fragility but was Afraid to Ask . . . . . 26 Disclosure: Nothing to Disclose Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 21 Disclosure: Nothing to Disclose Langer, Frederick P. Disability: Clinical Facts, Legal Fictions, and Practice Strategies. . . . . . . . . . . . . . . 43 Disclosure: Nothing to Disclose Langford, Carol A., MD, MHS ACR/ABIM Maintenance of Certification Learning Session - 2011 Update in Rheumatology . . . . . . . . . . . . . . . . . 19 Disclosure: Nothing to Disclose Plenary Session III . . . . . . . . . . . . . . . 91 Disclosure: Nothing to Disclose Vasculitis: Key Issues for the Clinician in Three Unique Diseases . . . . . . . . . . . . . . . . 96 Disclosure: Nothing to Disclose Lapidus, Sivia K., MD Periodic Fevers with Aphthous Stomatitis, Pharyngitis, and Adenitis . . . . . . . . . . . 91 Disclosure: Nothing to Disclose Laslop, Andrea, Univ-Prof, MD Biosimilar Products in the U.S. Market: Fact or Fiction. . . . . . . . . . . . . . . . . . . . .125 Disclosure: Nothing to Disclose Lau, Lester F., PhD Fibrosis: Novel Paradigms . . . . . . . . . . 64 Disclosure: Nothing to Disclose LaValley, Michael P., PhD To P or Not to P Knowing When the P-Value is Less than Useful . . . . . . . . . . . . . . . . 58 Disclosure: Nothing to Disclose Lawry, George V., MD Musculoskeletal Exam Skills I: General Musculoskeletal Examination for Arthritis . 58 Disclosure: McGraw-Hill medical publishers, 7 Musculoskeletal Exam Skills II: Regional Musculoskeletal Examination of the Neck and Low Back . . . . . . . . . . . . . . . . . . . . 87 Disclosure: McGraw-Hill medical publishers, 7 Musculoskeletal Exam Skills III: Regional Musculoskeletal Examination of the Shoulder and Knee . . . . . . . . . . . . . . . . . . . . 90 Disclosure: McGraw-Hill medical publishers, 7 2011 Program Book Lee, Jungwha, MPH, PhD Basic Statistical Concepts for the Medical Researcher . . . . . . . . . . . . . . . . . . . 63 Disclosure: Nothing to Disclose Lee, Leia A., MD The Three Ps of Dermatologic and Autoimmune Disease: Pyoderma, Panniculitis and Pemphigus/ Pemphigoid . . . . . . . . . . . . . . . . . . 91 Disclosure: Nothing to Disclose Lee, Yvonne C., MD Pain Pathways in Rheumatic Diseases . . . .125 Disclosure: Elan Corporation, 1; Forest Laboratories, 2; Merck Pharmaceuticals, 1; Novartis Pharmaceutical Corporation, 1 Pain: Pathophysiology and Clinical Assessment . . . . . . . . . . . . . . . . . . . . . . . . . 24 Disclosure: Elan Corporation, 1; Forest Laboratories, 2; Merck Pharmaceuticals, 1; Novartis Pharmaceutical Corporation, 1 Legault, Kimberly, MD Thieves’ Market: Show Me Your Best Cases. 71 Disclosure: Nothing to Disclose Leonard, Mary Beth, MD, MSCE Session II: Cross-Talk between Bone and Extra- Skeletal Organs . . . . . . . . . . . . . . . . 19 Disclosure: Nothing to Disclose Lightfoot, Robert W., MD ACR/ARHP Knowledge Bowl . . . . . . . . .113 Disclosure: Nothing to Disclose Limanni, Alex, MD Insurance Roundtable. . . . . . . . . . . . .113 Disclosure: Nothing to Disclose Lindwall, Elvira, MD ACR/ARHP Knowledge Bowl . . . . . . . . .113 Disclosure: Nothing to Disclose Lioté, Frédéric, MD, PhD Rheumatic Disease Update: Calcium Pyrophosphate Crystal Deposition Disease . 31 Disclosure: LGV, 9; Novartis Pharmaceutical Corporation, 5, 9; SOBI, 9 Little, Christopher B., BSc, MSc, BVMS, PhD Tools for Studying Joint Tissue Changes in Osteoarthritis . . . . . . . . . . . . . . . . . 34 Disclosure: Pfizer Inc, 2 Lockshin, Michael D., MD Curbside Consults - Ask the Professors . . . 59 Disclosure: Nothing to Disclose Mechanisms of Thrombosis in Systemic Autoimmune Disease . . . . . . . . . . . . 118 Disclosure: Nothing to Disclose Publishing in Peer-Reviewed Medical Journals . . . . . . . . . . . . . . . . . . . . . . . . . 33 Disclosure: Nothing to Disclose Loeser, Richard F., MD Osteoarthritis: A Disease of the Joint as an Organ. . . . . . . . . . . . . . . . . . . . . .107 Disclosure: Nothing to Disclose Osteoarthritis: Update 2011 . . . . . . . 55, 87 Disclosure: Nothing to Disclose Lohmander, Stefan, MD, PhD Tools for Studying Joint Tissue Changes in Osteoarthritis . . . . . . . . . . . . . . . . . 34 Disclosure: Nothing to Disclose Lories, Rik, MD, PhD Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 20 Disclosure: Abbott, Pfizer, 2; Pfizer, MSD, Abbott, Celgene, 5 Lovell, Daniel J., MD, MPH Update on Safety Issues in the Treatment of Rheumatic Diseases – From the FDA and Beyond . . . . . . . . . . . . . . . . . . . . . . . . .125 Disclosure: Abbott, 5; Amgen, 5; Astra-Zeneca Pharmaceutical, 5; Bristol-Meyers Squibb, 5; Centocor, Inc., 5; Hoffmann-La Roche Inc, 5; Novartis, Inc, 5; Pfizer Inc, 5; UBC., 5; Wyeth Pharmaceuticals, 5 Lowik, Clemens, PhD Session IV: Assessment of Bone Structure and Quality . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Nothing to Disclose Lynch, John, PhD The Osteoarthritis Initiative: A Database for Knee Osteoarthritis Research . . . . . . . . 31 Disclosure: Nothing to Disclose M Maas, James B., PhD Keynote Address: Sleep for Success! Everything You Must Know About Sleep, but Are Too Tired to Ask. . . . . . . . . . . . . . . . . . . . . . 29 Disclosure: Nothing to Disclose Mack, Matthias, MD New Concepts in the Autoimmune Pathogenesis of Interstitial Lung Diseases . . . . . . . . .106 Disclosure: Nothing to Disclose Maillard, Susan, MSc An Update in the Diagnosis and Management of Juvenile Dermatomyositis . . . . . . . . . . 86 Disclosure: Nothing to Disclose Maixner, William, DDS, PhD Pain Pathways in Rheumatic Diseases . . . .125 Disclosure: Algynomics, 1; NIH Grant, 2 Maksymowych, Walter P., MD Spondylarthropathies: Recent Insights . . . 87 Disclosure: Abbott Laboratories, 5; Amgen, 5; Bristol-Myers Squibb, 5; Eli Lilly and Company, 5; Merck Pharmaceuticals, 5; Pfizer Inc, 5 Malfait, Anne-Marie, MD, PhD Cytokine and Chemokine Regulation of Chronic Pain . . . . . . . . . . . . . . . . . . . . . . . 88 Disclosure: Pfizer Inc, 1, 5 Pain Pathways in Rheumatic Diseases . . . .125 Disclosure: Pfizer Inc, 1, 5 Mandelin II, Arthur M., MD, PhD Adult Musculoskeletal Lower Examinations. 87 Disclosure: Nothing to Disclose Adult Musculoskeletal Upper Examinations. 44 Disclosure: Nothing to Disclose Mandell, Brian F., MD, PhD Synovial Fluid Analysis and Crystal Identification . . . . . . . . . . . . . . . . . . . . . 87, 59, 30 Disclosure: Nothing to Disclose Mandl, Lisa A., MD, MPH Total Hip and Knee Replacements 2011: An Update for Rheumatologists . . . . . . . . . 74 Disclosure: Nothing to Disclose
Manzi, Susan, MD Biomarkers in Systemic Lupus Erythematosus: Where do we stand . . . . . . . . . . . . . 63 Disclosure: Anthera, 9; Bristol-Myers Squibb, 2, 9; Cephalon, 2, 9; Cypress Biosciences, Inc., 5; Human Genome Sciences, Inc., 2, 9; Immunomedics, Inc., 2; Medammune, Inc., 9; NIH, 2 Difficult to Treat Systemic Lupus Erythematosus: Case Studies . . . . . . . . . . . . . . . . . . 73 Disclosure: Anthera, 9; Bristol-Myers Squibb, 2, 9; Cephalon, 2, 9; Cypress Biosciences, Inc., 5; Human Genome Sciences, Inc., 2, 9; Immunomedics, Inc., 2; Medammune, Inc., 9; NIH, 2 Marder, Wendy, MD Deconstructing the Randomized Controlled Trial: Assessing the Study Quality of Level One Non-Drug Studies . . . . . . . . . . . . . . . 53 Disclosure: Nothing to Disclose Maricic, Michael J., MD Osteoporosis: Novel Treatments . . . . . . . 32 Disclosure: Amgen, 2; Eli Lilly and Company, 2; Genentech and Biogen IDEC Inc., 2; Merck Pharmaceuticals, 2; Novartis Pharmaceutical Corporation, 5; Proctor & Gamble Pharmaceuticals, 2 ACR REF Oscar S. Gluck, MD, Memorial Lectureship: Everything a Rheumatologist Should Know About Glucocorticoid-Induced Bone Fragility but was Afraid to Ask . . . . . 26 Disclosure: Nothing to Disclose Rheumatology Practice 101: Starting Out in Practice for The Graduating Fellow . . . . .113 Disclosure: Amgen, 2; Eli Lilly and Company, 2; Genentech and Biogen IDEC Inc., 2; Merck Pharmaceuticals, 2; Novartis Pharmaceutical Corporation, 5; Proctor & Gamble Pharmaceuticals, 2 Mariette, Xavier, MD Extra Glandular Manifestations of Sjögren’s Syndrome . . . . . . . . . . . . . . . . . . .107 Disclosure: GlaxoSmithKline, 5; Pfizer Inc, 2, 5; Roche Pharmaceuticals, 2, 5; UCB, 5 Mechanisms of Lymphoma Development in Systemic Autoimmune Disease. . . . . . . . 95 Disclosure: GlaxoSmithKline, 5; Pfizer Inc, 2, 5; Roche Pharmaceuticals, 2, 5; UCB, 5 Martinez-Lavin, Manuel, MD Fibromyalgia . . . . . . . . . . . . . . . . . . 80 Disclosure: Nothing to Disclose Fibromyalgia and Dysautonomia. . . . . . . 93 Disclosure: Nothing to Disclose Martini, Alberto, MD Juvenile Idiopathic Arthritis: Clinical Heterogeneity and the Genome . . . . . . . 59 Disclosure: Nothing to Disclose Marzan, Katherine AB, MD Preparing for Transition from Day One of Diagnosis to Adult Care . . . . . . . . . . . . 58 Disclosure: Nothing to Disclose Massarotti, Elena M., MD Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus . . . . . . . 32 Disclosure: EMD Serono, Roche, 2; UCB, Ampimmune, Bristol Myers Squibb, 5 Matsumoto, Alan K., MD Utilizing Media Relations to Build Your Practice . . . . . . . . . . . . . . . . . . . . . . . . . 29 Disclosure: Nothing to Disclose McCarthy, G M., MD Crystal: Pseudogout . . . . . . . . . . . . . . 62 Disclosure: Nothing to Disclose Crystals and Arthritis-Mechanisms of Inflammation and Joint Destruction . . . . . 44 Disclosure: Nothing to Disclose McClatchey, William M., MD Effective Use of Technology . . . . . . . . .113 Disclosure: Nothing to Disclose McClung, Michael, MD Metabolic Bone Disease . . . . . . . . . . .115 Disclosure: Merck Pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 5; Warner-Chilcott Pharmaceuticals, 5 McDougall, Jason J., PhD Pain Pathways in Rheumatic Diseases . . . .125 Disclosure: Nothing to Disclose McGonagle, Dennis, MB, PhD Enthesopathy: Spondylarthropathies and Beyond . . . . . . . . . . . . . . . . . . . . . 23 Disclosure: Nothing to Disclose McInnes, Iain B., PhD New Targets in Rheumatoid Arthritis: Syk, Jaks and Btk . . . . . . . . . . . . . . . . . . . . . 28 Disclosure: Astra Zeneca, 5; Pfizer Inc, 2 McLean, Robert R., DSc, MPH Are You Losing It How to Deal with Loss to Follow Up in Research Studies and Clinical Trials . . . . . . . . . . . . . . . . . . . . . . . . . 92 Disclosure: Nothing to Disclose Highlights from the 2011 ARHP Sessions . .117 Disclosure: Nothing to Disclose Introduction to Comparative Effectiveness Research Study Designs for Rheumatology Health Professionals . . . . . . . . . . . . .124 Disclosure: Nothing to Disclose McMahan, Zsuzsanna H., MD ACR/ARHP Knowledge Bowl . . . . . . . . .113 Disclosure: Nothing to Disclose Anemia of Inflammatory Disease . . . . . . 56 Disclosure: Nothing to Disclose Medsger, Thomas A., MD Session IV: Successes in Rheumatology Comparative Effectiveness Research. . . . . 22 Disclosure: Nothing to Disclose Melton, Alton, MD Immunodeficiency Syndromes . . . . . . . . 51 Disclosure: Nothing to Disclose Merkel, Peter A., MD, MPH Vasculitis: Key Issues for the Clinician in Three Unique Diseases . . . . . . . . . . . . . . . . 96 Disclosure: Actelion Pharmaceuticals US, 5; Avila, 5; Bellus Health, 5; Bristol-Myers Squibb, 2; Celgene, 2; Genentech and Biogen IDEC Inc., 2; Human Genome Sciences, Inc., 5; Nordic Group, 5; Protein Therapeutics, 2; Serono, 5 Vasculitis: Update . . . . . . . . . . . . . 62, 87 Disclosure: Actelion Pharmaceuticals US, 5; Avila, 5; Bellus Health, 5; Bristol-Myers Squibb, 2; Celgene, 2; Genentech and Biogen IDEC Inc., 2; Human Genome Sciences, Inc., 5; Nordic Group, 5; Protein Therapeutics, 2; Serono, 5 Merrell, Victoria A., PA-C, MPT Rehabilitation for the Clinician . . . . . . . . 43 Disclosure: Nothing to Disclose Merrill, J.T., MD Treatment of Lupus Nephritis . . . . . . . . 60 Disclosure: Aspreva, 2; Aspreva Vifor, Genentech, Bristol Myers Squibb, Pfizer, 5; Bristol Myers Squibb, 2; Genentech and Biogen IDEC Inc., 2 Messier, Stephen P., PhD ACR Plenary Session I: Discovery 2011 . . . 31 Disclosure: Nothing to Disclose Miceli-Richard, Corinne, MD, PhD Mechanisms of Lymphoma Development in Systemic Autoimmune Disease. . . . . . . . 95 Disclosure: Nothing to Disclose Michaud, Kaleb D., PhD Introduction to Comparative Effectiveness Research Study Designs for Rheumatology Health Professionals . . . . . . . . . . . . .125 Disclosure: Nothing to Disclose Mikuls, Ted R., MD 2011 Updated ACR Rheumatoid Arthritis Guidelines . . . . . . . . . . . . . . . . . . . 63 Disclosure: Nothing to Disclose Miller, Frederick W., MD, PhD Career Opportunities in Rheumatology: Making a Choice . . . . . . . . . . . . . . . . . . . .123 Disclosure: Nothing to Disclose Impact of Environmental Health on Autoimmunity . . . . . . . . . . . . . . . . . 34 Disclosure: Nothing to Disclose Miller, Richard J., PhD Cytokine and Chemokine Regulation of Chronic Pain . . . . . . . . . . . . . . . . . . . . . . . 88 Disclosure: Nothing to Disclose Miner, Jeffrey N., PhD Plenary Session II . . . . . . . . . . . . . . . 60 Disclosure: Ardea Biosciences, 1, 3; Scientific Advisor for Arman Tadbir Afagh - ARTA, 6 Molina, Rodolfo, MD Insurance Roundtable. . . . . . . . . . . . .113 Disclosure: Nothing to Disclose Monach, Paul A., MD, PhD Vasculitis: An Update . . . . . . . . . . . 80, 94 Disclosure: Bristol-Myers Squibb, 2; Genentech and Biogen IDEC Inc., 5 Moreland, Larry W., MD Rheumatoid Arthritis: Biological Agents 80, 113 Disclosure: Chemocentryx, 5; Crescendo, 5; Pfizer Inc, 5 Morrison, William, MD Musculoskeletal Imaging . . . . . . . . . . . 95 Disclosure: Apriomed, Inc, 9; GE Healthcare, 5 Moskowitz, Roland W., MD ACR REF Paul Klemperer, MD Memorial Lectureship: Osteoarthritis - Quo Vadis - Where are We Now - Where are We Going . . . . 89 Disclosure: Bioiberica, 5; Cyperss Bioscience, 5; Cypress Biosciences, Inc., 5; Endo Pharmaceuticals Inc., 5; Iroko Pharmaceuticals, 5; Johnson and Johnson, 5; Lilly Company, 5; Novartis Pharmaceutical Corporation, 8; Pfizer Inc, 8; Smith and Nephew, 5; Wyeth Pharmaceuticals, 5 2011 Program Book 331 Invited Speaker /Moderator Index
Page 1 and 2:
program B O O K Pre-Conference Cour
Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
Page 5 and 6:
TABLE OF CONTENTS POLICIES Copyrigh
Page 7 and 8:
TABLE OF CONTENTS ACR Immunology Up
Page 9 and 10:
TABLE OF CONTENTS Vasculitis Poster
Page 11 and 12:
However, the ACR continues to requi
Page 13 and 14:
MEETING NAVIGATION GUIDE To navigat
Page 15 and 16:
Newsroom Located in room W175c, use
Page 17:
Guided Poster Tours Guided poster t
Page 20 and 21:
FRIDAY November 4, 2011 9:15 am Ult
Page 22 and 23:
SATURDAY, NOVEMBER 5, 2011 12:00 -
Page 24 and 25:
SATURDAY November 5, 2011 8:35 am T
Page 26 and 27:
SATURDAY November 5, 2011 Pain: Pat
Page 28 and 29:
SUNDAY November 6, 2011 SUNDAY, NOV
Page 30 and 31:
SUNDAY November 6, 2011 Upon comple
Page 32 and 33:
EXHIBITS 10:00 am - 5:00 pm INNOVAT
Page 34 and 35:
SUNDAY November 6, 2011 ARHP SPECIA
Page 36 and 37:
SUNDAY November 6, 2011 W179b Rheum
Page 38 and 39:
3:15 pm 732. Notch Signaling Pathwa
Page 40 and 41:
SUNDAY November 6, 2011 3:15 pm 756
Page 42 and 43:
SUNDAY November 6, 2011 Children’
Page 44 and 45:
Page 46 and 47:
3:30 pm Demonstration and Practice
Page 48 and 49:
Yasser M. El Miedany 1 , Maha El Ga
Page 50 and 51:
SUNDAY November 6, 2011 48 Musculos
Page 52 and 53:
Page 54 and 55:
SUNDAY November 6, 2011 52 4:55 pm
Page 56 and 57:
MONDAY, NOVEMBER 7, 2011 ACR/ARHP R
Page 58 and 59:
MONDAY November 7, 2011 W185a Scler
Page 60 and 61:
MONDAY November 7, 2011 Upon comple
Page 62 and 63:
Upon completion of this session, pa
Page 64 and 65:
MONDAY November 7, 2011 W187b Basic
Page 66 and 67:
MONDAY November 7, 2011 2:30 pm Cel
Page 68 and 69:
MONDAY November 7, 2011 Indianapoli
Page 70 and 71:
3:45 pm 1628. Association of Knee P
Page 72 and 73:
MONDAY November 7, 2011 Glostrup, C
Page 74 and 75:
MONDAY November 7, 2011 3:33 pm A R
Page 76 and 77:
MONDAY November 7, 2011 4:30 pm Ris
Page 78 and 79:
Institutet, Stockholm, Sweden, 6 Un
Page 80 and 81:
5:45 pm 1700. Successful Dose De-Es
Page 82 and 83:
MONDAY November 7, 2011 Michigan, A
Page 84 and 85:
MONDAY November 7, 2011 4:45 pm 172
Page 86 and 87:
MONDAY November 7, 2011 5:25 pm Imp
Page 88 and 89:
TUESDAY November 8, 2011 ARHP CONCU
Page 90 and 91:
TUESDAY November 8, 2011 9:25 am Is
Page 92 and 93:
ACR PRACTICE ISSUE 9:30 - 10:30 am
Page 94 and 95:
TUESDAY November 8, 2011 noon 2431.
Page 96 and 97:
TUESDAY November 8, 2011 W186b Vasc
Page 98 and 99:
ACR CLINICAL SYMPOSIA 2:30 - 4:00 p
Page 100 and 101:
TUESDAY November 8, 2011 3:45 pm 24
Page 102 and 103:
TUESDAY November 8, 2011 University
Page 104 and 105:
TUESDAY November 8, 2011 and Oncolo
Page 106 and 107:
Italy, 3 Hospital Universitario La
Page 108 and 109:
3:10 pm Case Study Diane V. Lacaill
Page 110 and 111:
• discuss the evidence to support
Page 112 and 113:
TUESDAY November 8, 2011 4:45 pm 25
Page 114 and 115:
5:15 pm 2532. Selection of Patients
Page 116 and 117:
TUESDAY November 8, 2011 ACR/ARHP C
Page 118 and 119:
WEDNESDAY, NOVEMBER 9, 2011 ACR/ARH
Page 120 and 121:
9:00 am Mechanisms of Thrombosis in
Page 122 and 123:
WEDNESDAY November 9, 2011 A. Kopec
Page 124 and 125:
WEDNESDAY November 9, 2011 9:15 am
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
WEDNESDAY November 9, 2011 Graduate
Page 132 and 133:
11:00 am The Process: Defining Appr
Page 134 and 135:
ACR Poster Session A 11. Myocardial
Page 136 and 137:
ACR Poster Session A 37. Regulation
Page 138 and 139:
ACR Poster Session A 64. Interleuki
Page 140 and 141:
ACR Poster Session A Mexico City, M
Page 142 and 143:
ACR Poster Session A 121. An Analys
Page 144 and 145:
ACR Poster Session A 146. National
Page 146 and 147:
ACR Poster Session A 165. Genome-Wi
Page 148 and 149:
ACR Poster Session A 185. US Examin
Page 150 and 151:
ACR Poster Session A Jones 1 , Andr
Page 152 and 153:
ACR Poster Session A Gerald J. D. H
Page 154 and 155:
ACR Poster Session A 258. Etanercep
Page 156 and 157:
ACR Poster Session A GA, 6 Hospital
Page 158 and 159:
ACR Poster Session A 305. Pathway-B
Page 160 and 161:
ACR Poster Session A 328. Near Miss
Page 162 and 163:
ACR Poster Session A 351. A Novel M
Page 164 and 165:
ACR Poster Session A Sugihara 6 , K
Page 166 and 167:
ACR Poster Session A 398. Rituximab
Page 168 and 169:
ACR Poster Session A & Johnson Phar
Page 170 and 171:
ACR Poster Session A 436. Predicted
Page 172 and 173:
ACR Poster Session A Tomomi Tsuru 1
Page 174 and 175:
ACR Poster Session A 479. Follow up
Page 176 and 177:
ACR Poster Session A 496. A Chimeri
Page 178 and 179:
ACR Poster Session A 518. Associati
Page 180 and 181:
ACR Poster Session A Piestany, Slov
Page 182 and 183:
ACR Poster Session A 576. Fn14 Defi
Page 184 and 185:
ACR Poster Session A 593. Plasma Le
Page 186 and 187:
ACR Poster Session A 611. Why Do Lu
Page 188 and 189:
ACR Poster Session A 634. Associati
Page 190 and 191:
ACR Poster Session A Alarcon-Riquel
Page 192 and 193:
ACR Poster Session A Laboratories,
Page 194 and 195:
ACR Poster Session A Movsisyan, Lid
Page 196 and 197:
ACR Poster Session A Th1 Cells Expa
Page 198 and 199:
ACR/ARHP Poster Session B College o
Page 200 and 201:
ACR/ARHP Poster Session B 920. Econ
Page 202 and 203:
ACR/ARHP Poster Session B Study. A.
Page 204 and 205:
ACR/ARHP Poster Session B 974. Dise
Page 206 and 207:
ACR/ARHP Poster Session B 1001. Mic
Page 208 and 209:
ACR/ARHP Poster Session B 206 Khann
Page 210 and 211:
ACR/ARHP Poster Session B 208 Pulmo
Page 212 and 213:
ACR/ARHP Poster Session B Swearinge
Page 214 and 215:
ACR/ARHP Poster Session B 212 Felds
Page 216 and 217:
ACR/ARHP Poster Session B 214 Corbi
Page 218 and 219:
ACR/ARHP Poster Session B 1161. End
Page 220 and 221:
ACR/ARHP Poster Session B 1182. Uri
Page 222 and 223:
ACR/ARHP Poster Session B 1205. A S
Page 224 and 225:
ACR/ARHP Poster Session B 222 Murth
Page 226 and 227:
ACR/ARHP Poster Session B San Diego
Page 228 and 229:
ACR/ARHP Poster Session B 1266. Eva
Page 230 and 231:
ACR/ARHP Poster Session B 1296. Pat
Page 232 and 233:
ACR/ARHP Poster Session B 230 1320.
Page 234 and 235:
ACR/ARHP Poster Session B 1348. Syn
Page 236 and 237:
ACR/ARHP Poster Session B 1375. Ant
Page 238 and 239:
ACR/ARHP Poster Session B 1398. Cli
Page 240 and 241:
ACR/ARHP Poster Session B Baltimore
Page 242 and 243:
ACR/ARHP Poster Session B 1451. Ele
Page 244 and 245:
ACR/ARHP Poster Session B Sclerosis
Page 246 and 247:
ACR/ARHP Poster Session B 1496. Evi
Page 248 and 249:
ACR/ARHP Poster Session B 1518. Pro
Page 250 and 251:
ACR/ARHP Poster Session B Hagen 1 ,
Page 252 and 253:
ACR/ARHP Poster Session B ARHP Clin
Page 254 and 255:
ACR/ARHP Poster Session C Karl Eger
Page 256 and 257:
ACR/ARHP Poster Session C Tampere S
Page 258 and 259:
ACR/ARHP Poster Session C 256 1 Jun
Page 260 and 261:
ACR/ARHP Poster Session C Universit
Page 262 and 263:
ACR/ARHP Poster Session C 1864. Epi
Page 264 and 265:
ACR/ARHP Poster Session C 262 Hospi
Page 266 and 267:
ACR/ARHP Poster Session C 2 Biogen
Page 268 and 269:
ACR/ARHP Poster Session C 1945. Cir
Page 270 and 271:
ACR/ARHP Poster Session C 268 1974.
Page 272 and 273:
ACR/ARHP Poster Session C 2003. Eff
Page 274 and 275:
ACR/ARHP Poster Session C Hosp Gast
Page 276 and 277:
ACR/ARHP Poster Session C Toronto,
Page 278 and 279:
ACR/ARHP Poster Session C Francisco
Page 280 and 281:
ACR/ARHP Poster Session C 2105. Inc
Page 282 and 283: ACR/ARHP Poster Session C Universit
Page 284 and 285: ACR/ARHP Poster Session C 282 2151.
Page 290 and 291: ACR/ARHP Poster Session C 2217. Lon
Page 292 and 293: ACR/ARHP Poster Session C Research
Page 294 and 295: ACR/ARHP Poster Session C 2258. sIL
Page 296 and 297: ACR/ARHP Poster Session C 2290. The
Page 298 and 299: ACR/ARHP Poster Session C Universit
Page 300 and 301: ACR/ARHP Poster Session C 2345. IL-
Page 302 and 303: ACR/ARHP Poster Session C 2376. Gra
Page 304 and 305: ACR/ARHP Poster Session C 2399. Spe
Page 306 and 307: REF Industry Roundtable-supported S
Page 308 and 309: REF Industry Roundtable-supported S
Page 310 and 311: Industry-supported POST-CONFERENCE
Page 312 and 313: CERTIFICATES OF CME CREDIT OR PARTI
Page 314 and 315: 2011 ACR/ARHP Annual Meeting Leader
Page 316 and 317: 2011 ACR/ARHP Annual Meeting Leader
Page 318 and 319: EXHIBITORS Abbott Pharmaceuticals B
Page 320 and 321: EXHIBITORS Lippincott, Williams and
Page 322 and 323: acknowledgements The ACR, the ARHP
Page 324 and 325: Invited Speaker /Moderator Index 32
Page 328 and 329: Invited Speaker /Moderator Index Ev
Page 334 and 335: Invited Speaker /Moderator Index Mu
Page 336 and 337: Invited Speaker /Moderator Index Om
Page 338 and 339: Invited Speaker /Moderator Index St
Page 340 and 341: Invited Speaker /Moderator Index Wi
Page 342 and 343: aBSTRACT author Index 340 Alpers, C
Page 344 and 345: aBSTRACT author Index Bawa, WA 259
Page 346 and 347: aBSTRACT author Index 344 Broder, A
Page 348 and 349: aBSTRACT author Index 346 Chaves, L
Page 350 and 351: aBSTRACT author Index 348 Dalbeth,
Page 352 and 353: aBSTRACT author Index Eastman, PS 3
Page 354 and 355: aBSTRACT author Index 352 Fragoso-L
Page 356 and 357: aBSTRACT author Index Gordon, C 4,
Page 358 and 359: aBSTRACT author Index Hemmati, I 13
Page 360 and 361: aBSTRACT author Index 358 Ishigatsu
Page 362 and 363: aBSTRACT author Index 360 Keeling,
Page 364 and 365: aBSTRACT author Index 362 Kumar, V
Page 366 and 367: aBSTRACT author Index 364 Lim, M 13
Page 368 and 369: aBSTRACT author Index 366 Marshall,
Page 370 and 371: aBSTRACT author Index 368 MMF/AZA L
Page 372 and 373: aBSTRACT author Index 370 Noel, D 1
Page 374 and 375: aBSTRACT author Index 372 Pawlita,
Page 376 and 377: aBSTRACT author Index 374 Ramos, I
Page 378 and 379: aBSTRACT author Index 376 Rönnblom
Page 380 and 381: aBSTRACT author Index 378 Shaykevic
Page 382 and 383:
aBSTRACT author Index Su, J 22, 139
Page 384 and 385:
aBSTRACT author Index 382 Tomcik, M
Page 386 and 387:
aBSTRACT author Index 384 Villeneuv
Page 388 and 389:
aBSTRACT author Index 386 Wu, X 650
Page 390 and 391:
abstract keyword Index 388 18FDG PE
Page 392 and 393:
abstract keyword Index 2092, 2113,
Page 394 and 395:
abstract keyword Index 392 macropha
Page 396 and 397:
abstract keyword Index 387, 388, 38
Page 398 and 399:
Abstract Moderator disclosure A Ano
Page 400 and 401:
Abstract Moderator disclosure Jonas
Page 402 and 403:
V van der Heijde, Desiree, MD, PhD
Page 404 and 405:
Notes 402 2011 Program Book
Page 406 and 407:
immunosuppressive agents is not rec
Page 408:
In appropriate patients with psoria
show all

Program Book - Confex

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?